Details for New Drug Application (NDA): 205065

✉ Email this page to a colleague

NDA 205065 describes KUVAN, which is a drug marketed by Biomarin Pharm and is included in two NDAs. It is available from one supplier. There are ten patents protecting this drug and three Paragraph IV challenges. Additional details are available on the KUVAN profile page.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sapropterin dihydrochloride profile page.

Summary for 205065

Tradename:	KUVAN
Applicant:	Biomarin Pharm
Ingredient:	sapropterin dihydrochloride
Patents:	6

Pharmacology for NDA: 205065

Mechanism of Action	Breast Cancer Resistance Protein Inhibitors P-Glycoprotein Inhibitors Phenylalanine Hydroxylase Activators

Suppliers and Packaging for NDA: 205065

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065	NDA	BioMarin Pharmaceutical Inc.	68135-301	68135-301-22	30 PACKET in 1 CARTON (68135-301-22) / 1 POWDER, FOR SOLUTION in 1 PACKET (68135-301-11)
KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065	NDA	BioMarin Pharmaceutical Inc.	68135-482	68135-482-11	30 PACKET in 1 CARTON (68135-482-11) / 1 POWDER, FOR SOLUTION in 1 PACKET (68135-482-10)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;ORAL			Strength	100MG/PACKET
Approval Date:	Dec 19, 2013	TE:	AB	RLD:	Yes
Patent:	7,566,714*PED	Patent Expiration:	May 17, 2025	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	7,612,073*PED	Patent Expiration:	May 17, 2025	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	8,067,416*PED	Patent Expiration:	May 17, 2025	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 205065

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-001	Dec 19, 2013	7,566,714*PED	⤷ Get Started Free
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-002	Oct 27, 2015	7,566,714*PED	⤷ Get Started Free
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-002	Oct 27, 2015	RE43797*PED	⤷ Get Started Free
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-001	Dec 19, 2013	RE43797*PED	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.